Fibroblast Growth Factor-21 As a Novel Metabolic Factor for Regulating Thrombotic Homeostasis

Overview

Journal Sci Rep

Specialty Science

Date 2022 Jan 11

PMID 35013379

Authors

Shuai Li

Haibo Jia

Zhihang Liu

Nan Wang

Xiaochen Guo

Muhua Cao

Fang Fang

Jiarui Yang

Junyan Li

Qi He

Rui Guo

Teng Zhang

Kai Kang

Zongbao Wang

Shijie Liu

Yukai Cao

Xinghao Jiang

Guiping Ren

Kai Wang

Bo Yu

Wei Xiao

Deshan Li

Affiliations

Soon will be listed here.

Abstract

Fibroblast growth factor-21 (FGF-21) performs a wide range of biological functions in organisms. Here, we report for the first time that FGF-21 suppresses thrombus formation with no notable risk of bleeding. Prophylactic and therapeutic administration of FGF-21 significantly improved the degree of vascular stenosis and reduced the thrombus area, volume and burden. We determined the antithrombotic mechanism of FGF-21, demonstrating that FGF-21 exhibits an anticoagulant effect by inhibiting the expression and activity of factor VII (FVII). FGF-21 exerts an antiplatelet effect by inhibiting platelet activation. FGF-21 enhances fibrinolysis by promoting tissue plasminogen activator (tPA) expression and activation, while inhibiting plasminogen activator inhibitor 1 (PAI-1) expression and activation. We further found that FGF-21 mediated the expression and activation of tPA and PAI-1 by regulating the ERK1/2 and TGF-β/Smad2 pathways, respectively. In addition, we found that FGF-21 inhibits the expression of inflammatory factors in thrombosis by regulating the NF-κB pathway.

Citing Articles

Association of plasminogen activator inhibitor-1 and fibroblastic growth factor 21 in 3 groups of type 2 diabetes: Without overweight/obesity, free of insulin resistance, and without hepatosteatosis.

Takebe N, Hasegawa Y, Matsushita Y, Chiba H, Onodera K, Kinno H Medicine (Baltimore). 2023; 102(35):e34797.

PMID: 37657012 PMC: 10476825. DOI: 10.1097/MD.0000000000034797.

Fibroblast growth factor 21 resistance is associated with body shape in patients with type 2 diabetes complicating hypertension.

Gan J, Duan Z, Tang L, Liu Z, Tian H, Wu M Front Cardiovasc Med. 2023; 10:1168047.

PMID: 37424900 PMC: 10325616. DOI: 10.3389/fcvm.2023.1168047.

Mechanism of fibroblast growth factor 21 in cardiac remodeling.

Zhao Z, Cui X, Liao Z Front Cardiovasc Med. 2023; 10:1202730.

PMID: 37416922 PMC: 10322220. DOI: 10.3389/fcvm.2023.1202730.

Biocompatible Macroion/Growth Factor Assemblies for Medical Applications.

Michna A, Pomorska A, Ozcan O Biomolecules. 2023; 13(4).

PMID: 37189357 PMC: 10136312. DOI: 10.3390/biom13040609.

Exercise-Induced Fibroblast Growth Factor-21: A Systematic Review and Meta-Analysis.

Kim H, Jung J, Park S, Joo Y, Lee S, Sim J Int J Mol Sci. 2023; 24(8).

PMID: 37108444 PMC: 10139099. DOI: 10.3390/ijms24087284.

References

Sood V, Luke C, Deatrick K, Baldwin J, Miller E, Elfline M . Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism. Thromb Haemost. 2010; 104(6):1174-83. DOI: 10.1160/TH10-03-0184. View

Eckly A, Hechler B, Freund M, Zerr M, Cazenave J, Lanza F . Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemost. 2011; 9(4):779-89. DOI: 10.1111/j.1538-7836.2011.04218.x. View

Melchor J, Pawlak R, Strickland S . The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci. 2003; 23(26):8867-71. PMC: 6740393. View

Irigoyen J, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y . The plasminogen activator system: biology and regulation. Cell Mol Life Sci. 2001; 56(1-2):104-32. PMC: 11146966. DOI: 10.1007/pl00000615. View

Li W, Nieman M, Sen Gupta A . Ferric Chloride-induced Murine Thrombosis Models. J Vis Exp. 2016; (115). PMC: 5091988. DOI: 10.3791/54479. View

Li D, Chen K, Sinha N, Zhang X, Wang Y, Sinha A . The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res. 2005; 65(4):907-12. DOI: 10.1016/j.cardiores.2004.11.027. View

Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt K, Goetz R . BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A. 2007; 104(18):7432-7. PMC: 1855074. DOI: 10.1073/pnas.0701600104. View

Yu Y, He J, Li S, Song L, Guo X, Yao W . Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway. Int Immunopharmacol. 2016; 38:144-52. DOI: 10.1016/j.intimp.2016.05.026. View

Zhang Y, Whaley-Connell A, Sowers J, Ren J . Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management. Pharmacol Ther. 2018; 191:1-22. PMC: 6195437. DOI: 10.1016/j.pharmthera.2018.06.004. View

10.

Ye X, Qi J, Wu Y, Yu D, Xu P, Li S . Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice. Diabetes Metab. 2014; 41(1):82-90. DOI: 10.1016/j.diabet.2014.09.001. View

11.

Xu P, Zhang Y, Liu Y, Yuan Q, Song L, Liu M . Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways. Toxicol Appl Pharmacol. 2015; 290:43-53. DOI: 10.1016/j.taap.2015.11.012. View

12.

Rajagopalan S, Somers E, Brook R, Kehrer C, Pfenninger D, Lewis E . Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. 2004; 103(10):3677-83. DOI: 10.1182/blood-2003-09-3198. View

13.

Morrissey J, Macik B, Neuenschwander P, Comp P . Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993; 81(3):734-44. View

14.

Owen B, Mangelsdorf D, Kliewer S . Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab. 2014; 26(1):22-9. PMC: 4277911. DOI: 10.1016/j.tem.2014.10.002. View

15.

Dutchak P, Katafuchi T, L Bookout A, Choi J, Yu R, Mangelsdorf D . Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell. 2012; 148(3):556-67. PMC: 3273727. DOI: 10.1016/j.cell.2011.11.062. View

16.

Rectenwald J, Myers Jr D, Hawley A, Longo C, Henke P, Guire K . D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb Haemost. 2006; 94(6):1312-7. DOI: 10.1160/TH05-06-0426. View

17.

Kurosu H, Choi M, Ogawa Y, Dickson A, Goetz R, Eliseenkova A . Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007; 282(37):26687-26695. PMC: 2496965. DOI: 10.1074/jbc.M704165200. View

18.

Planavila A, Redondo-Angulo I, Villarroya F . FGF21 and Cardiac Physiopathology. Front Endocrinol (Lausanne). 2015; 6:133. PMC: 4553397. DOI: 10.3389/fendo.2015.00133. View

19.

Cheng Y, Zhang J, Guo W, Li F, Sun W, Chen J . Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy. Free Radic Biol Med. 2016; 93:94-109. PMC: 7446394. DOI: 10.1016/j.freeradbiomed.2016.02.002. View

20.

Naik M, Nigam A, Manrai P, Millili P, Czymmek K, Sullivan M . CIB1 deficiency results in impaired thrombosis: the potential role of CIB1 in outside-in signaling through integrin alpha IIb beta 3. J Thromb Haemost. 2009; 7(11):1906-14. PMC: 7034629. DOI: 10.1111/j.1538-7836.2009.03581.x. View